Hydrocortisone Amdipharm Uk Limited (Hydrocortisone Sodium Phosphate)

Hydrocortisone Amdipharm UK Limited is a prescription‑only injectable medication that contains the corticosteroid hydrocortisone sodium phosphate. It is supplied as a sterile solution for intramuscular or intravenous administration and is marketed within the European Union. The product is intended for professional use under medical supervision, follows EU glucocorticoid regulations, and is packaged in single‑dose vials without additional active excipients or preservatives, ensuring stability and sterility.

Hydrocortisone sodium phosphate injection is employed in clinical practice for several glucocorticoid‑related indications.

- Acute adrenal insufficiency or crisis, requiring rapid glucocorticoid replacement. - Severe allergic reactions such as anaphylaxis where fast anti‑inflammatory action is needed. - Management of septic shock or systemic inflammatory response to stabilize hemodynamics. - Replacement therapy in patients with congenital adrenal hyperplasia or other chronic cortisol deficiency. - Pre‑operative reduction of airway or upper‑respiratory tract edema to facilitate intubation. - Adjunctive therapy in selected autoimmune disorders when high‑dose systemic steroids are indicated.

Systemic administration of hydrocortisone sodium phosphate may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common: - Elevated blood glucose levels, especially in diabetic patients. - Fluid retention leading to mild edema or weight gain. - Mood changes such as irritability, anxiety, or insomnia. - Gastrointestinal discomfort, including nausea or dyspepsia. - Skin thinning, easy bruising, or delayed wound healing. - Headache or dizziness.

Serious: - Suppression of the hypothalamic‑pituitary‑adrenal axis, risking adrenal crisis on abrupt discontinuation. - Increased susceptibility to severe infections, including bacterial, viral, or fungal. - Rare but severe allergic reactions such as anaphylaxis or serum sickness. - Osteonecrosis, severe osteoporosis, or pathological fractures with prolonged therapy.

When prescribing hydrocortisone sodium phosphate, clinicians should consider several precautionary measures to minimize risks and ensure safe use.

- Assess baseline blood glucose and monitor during therapy. - Evaluate for active infections; avoid use in uncontrolled systemic fungal infections. - Use the lowest effective dose and limit duration to reduce adrenal suppression. - Monitor blood pressure and electrolytes, especially potassium, during prolonged therapy. - Consider bone health; supplement calcium and vitamin D if long‑term use is anticipated. - Taper gradually rather than abrupt discontinuation to prevent adrenal crisis.

Hydrocortisone sodium phosphate can interact with other medicines, influencing its efficacy or increasing the risk of adverse effects.

Avoid: - Strong CYP3A4 inducers such as rifampin, which may reduce glucocorticoid plasma concentrations. - Live or attenuated vaccines, because immunosuppression can diminish vaccine effectiveness or increase infection risk. - Concurrent use with anticoagulants like warfarin without close monitoring, as corticosteroids may potentiate anticoagulant effects.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs), which together may raise the risk of gastrointestinal ulceration or bleeding. - Diuretics, especially thiazides, which can exacerbate hypokalemia when combined with corticosteroids. - Antidiabetic agents, since glucocorticoids can raise blood glucose and may require dose adjustments. - ACE inhibitors or ARBs, as fluid retention from steroids may affect blood pressure control.